Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LADYBUG: GLPG3970 in Rheumatoid Arthritis
NCT04577781Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing GLPG3970 with Placebo (2 arms). Primary endpoint: Change From Baseline in Disease Activity Score 28 using C-Reactive Protein at 6 weeks. Started Oct 2020; status: completed.
02
Drugs
GLPG3970
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04577781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577781.